AltaVoice was acquired by Invitae Corp. in a transaction handled by a team of Pillsbury lawyers. In exchange for Invitae buying out all of AltaVoice’s stock, the company was given $5 million in Invitae stock. Deal terms also allow for an additional $10 million in Invitae stock to be issued if certain future milestones are reached.

Formerly known as PatientCrossroads, AltaVoice is a patient-centered data company and, before this deal, was privately owned. The company’s technology is intended for the collection, curation, coordination and delivery of safeguarded data from both patients and clinicians.

Invitae Corp. is a San Francisco-based provider of genetic testing services. Invitae believes the combination of their genetic testing business and AltaVoice’s patient database will help diagnose and treat hereditary disease, according to Daily Journal.

The Pillsbury team was led by San Diego North County Corporate & Securities partner Mike Hird and included Tax partner Brian Wainwright and Executive Compensation & Benefits partner Cindy Schlaefer, both based in Silicon Valley. Also on the team was associate Dusty Wolverton.